Veristat Congratulates Agios on the FDA Approval of TIBSOVO®
The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
SOUTHBOROUGH, MA –...
Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies...
Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That...
Veristat Recognized for a Third Consecutive Year on the Inc. 5000 List of America’s...
Veristat’s Growth Positively Impacts Our Ability to Help Clients Achieve Regulatory Approval of their Life-Changing and Life-Saving Therapies
Veristat and AOBiome Establish a Preferred Partnership To Support Ongoing & Impending...
SOUTHBOROUGH, MA – June 19, 2017 – Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome, ...
Veristat Congratulates TESARO on the FDA Approval of ZEJULA™
SOUTHBOROUGH, MA – May 30, 2017 – Veristat, a full service Clinical Research Organization (CRO), congratulates TESARO, Inc. on the approval...
Veristat Acknowledged on Boston Business Journal’s “Fast 50” List for a Second Consecutive...
Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts
Veristat Opens New Office in North Carolina Today
Veristat announced today the official opening of its new office in Morrisville, NC.
Veristat Appoints James Roach, MD as Chief Medical Officer
Veristat Strengthens its Clinical Operations, Medical and Regulatory Affairs Offerings
SOUTHBOROUGH, MA – November 07, 2016 – Veristat...Veristat Formalizes its Strategic Decision Consulting Services
SOUTHBOROUGH, MA – November 01, 2016 – Veristat, a full-service consultative Clinical Research Organization (CRO), announced today the formal...